Seeking Alpha

Seeking Alpha Portfolio App for iPad

7,217 people get DNDN articles and Market Currents by email alert.

Get email alerts on DNDN »

DNDN

Dendreon Corporation

5/22/2013, 10:13 AM ET

Quote & Headlines Market Currents StockTalk

All
| Earnings
| Dividends
| M&A
| On the move

Friday, May 10, 8:17 AM Dendreon's (DNDN) price target is shaved to $1 by BAML's Rachael McMinn (the axe, according to Notable Calls), who says even this doesn't take into account additional potential dilution. The company's underwater $648M in convertible debt with "no clear path to profitability provides a serious challenge to keep the business in operation beyond 2014." More: Citi downgrades to Sell with $3 PT, and Blair cuts its PT to $2. Shares -4.2% to $3.86 premarket. Comment! [Healthcare, On the Move]
Thursday, May 9, 2:37 PM Dendreon (DNDN -14.4%) retests its lows for the day as the Street begins to weigh in on its Q1 miss and dismal Provenge sales numbers. Stifel Nicolaus cuts the shares to Sell, calling Provenge "hopeless," and saying the company is likely to burn through its cash long before it ever reaches breakeven, and faces the possiblity of bankruptcy before the end of FY14. Roth Capital also downgrades the stock to Sell as well. 1 Comment [Healthcare, On the Move, Earnings]
Thursday, May 9, 11:42 AM In its call earlier, Dendreon (DNDN -12%) CEO John Johnson attributed its big Q1 miss on Provenge sales to increased competition, with the hit coming hardest in its smaller accounts which are less experienced with injectable therapies like DNDN's. But the veracity in today's selloff may be more closely linked to DNDN's sizeable chunk of convertible notes expiring in 2014 and 2016. Without any real operating income, Seeking Alpha contributor Brian Wilson thinks shareholders are facing some massive dilution on the horizon. (Webcast). 1 Comment [Healthcare, Earnings, On the Move]
Thursday, May 9, 10:03 AM Dendreon (DNDN -16%) plummets following its earnings miss with Provenge sales of just $67.6M vs. $82M a year ago, and against consensus of around $80M (and low-ball estimates in the low $70M area). "We are seeing an improvement in enrollments," says CEO John Johnson. "As we leverage the power of our DTC campaign, we are confident in our ability to grow Provenge year over year." The earnings call is underway. (PR) Comment! [Healthcare, On the Move, Earnings]
Thursday, May 9, 8:35 AM Dendreon (DNDN): Q1 EPS of -$0.48 misses by $0.01. Revenue of $67.6M misses by $12.55M. (PR) Comment! [Earnings, Breaking News, Healthcare]
Thursday, May 9, 8:30 AM Shares of Dendreon (DNDN) are halted with news pending. (Nasdaq T-1 halt) Comment! [Healthcare]
Thursday, May 9, 12:05 AM Notable earnings before Thursday’s open: AES, AGU, ALR, AM, AMRC, APA, BAM, BCE, CBB, CNSL, CTB, CVC, DF, DISH, DNDN, GLP, GTIV, IRC, KEM, KIOR, MEA, NPSP, OWW, PCP, SNE, SNSS, SPH, SRPT, TK, TNK, VICL, VNDA, WAC, WFR, WIN, WWAV, XRAY Comment! [Earnings]
Wednesday, May 8, 5:30 PM Notable earnings before Thursday’s open: AES, AGU, ALR, AM, AMRC, APA, BAM, BCE, CBB, CNSL, CTB, CVC, DF, DISH, DNDN, GLP, GTIV, IRC, KEM, KIOR, MEA, NPSP, OWW, PCP, SNE, SNSS, SPH, SRPT, TK, TNK, VICL, VNDA, WAC, WFR, WIN, WWAV, XRAY Comment! [Earnings]
Monday, March 18, 9:34 AM Dendreon (DNDN -1.3%) agrees to pay $40M to settle a class-action investor lawsuit that alleges that the company made "false or misleading statements," particularly about its Provenge cancer drug. Dendreon continues to deny that it made such statements, and says its insurers will pay $38M of the settlement. (PR) 1 Comment [Healthcare]
Monday, February 25, 1:40 PM Dendreon (DNDN +0.5%) moves up after its Q4 easily beat estimates earlier today. Community accounts, which represent 71% of total sales, were up from 58% Y/Y, with urology +25% overall Q/Q, and oncology up 4%. Comment! [Healthcare, On the Move, Earnings]
Monday, February 25, 7:32 AM Dendreon (DNDN): Q4 EPS of -$0.30 beats by $0.20. Revenue of $85.5M beats by $2.62M. (PR) Comment! [Earnings, Breaking News, Healthcare]
Monday, February 25, 12:05 AM Notable earnings before Monday’s open: ARIA, BGC, CTB, CWH, DDD, DNDN, FE, HL, HTZ, KWK, LOW, SFL Comment! [Earnings]
Sunday, February 24, 5:30 PM Notable earnings before Monday’s open: ARIA, BGC, CTB, CWH, DDD, DNDN, FE, HL, HTZ, KWK, LOW, SFL Comment! [Earnings]
Thursday, February 14, 11:49 AM Dendreon (DNDN -1.6%) slips after Maxim downgraded the shares to Sell today, citing concerns over Provenge sales. The firm also lowers its price target to $4.00. 3 Comments [Healthcare, On the Move]
Monday, February 11, 3:02 PM A genetically modified smallpox vaccine has been shown to shrink tumors in liver cancer patients and extends survival more than a year, a recent study found. The therapy, from closely held Jennerex, is called JX-594, or Pexa-Vec, and is currently being tested in people with advanced hepatocellular carcinoma. Treatment options for this advanced type of cancer are limited, and San Francisco-based Jennerex is competing with drug behemoths such as Amgen (AMGN -1.5%) and Merck (MRK +0.4%) in the space, as well as others such as Oncolytics Biotech (ONCY -5%) and Dendreon (DNDN -3.3%). 6 Comments
Monday, January 14, 9:09 AM Premarket gainers: AZK +29%. CUR +14%. AVNW +13%. HWD +11%. VRNT +10%. NICE +8%. FIO +6%. FRAN +6%. DNDN +5%. ALU +6%.
Losers: NTE -11%. CRUS -6%. Comment! [On the Move]

1
2
3
4
5
6
...
11
Next Page